First national surveillance of susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel

Diagnostic Microbiology and Infectious Disease

Volumn 57, Issue 2, 2007, Pages 201-205

  Colodner, Raul ^a   Samra, Zmira ^b   Keller, Nathan ^c   Sprecher, Hanna ^d   Block, Colin ^e   Peled, Nehama ^f   Lazarovitch, Tzilia ^g   Bardenstein, Rita ^h   Schwartz Harari, Orna ⁱ   Carmeli, Yehuda ^j  

^a HAEMEK MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d RAMBAM MEDICAL CENTER   (Israel)

^e HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^g ASSAF HAROFEH MEDICAL CENTER   (Israel)

^h KAPLAN MEDICAL CENTER   (Israel)

ⁱ WOLFSON MEDICAL CENTER   (Israel)

^j TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

more..

Author keywords

Lactamase; Escherichia coli; Israel

Indexed keywords

AMIKACIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CROSS RESISTANCE; DRUG SENSITIVITY; ESCHERICHIA COLI; HOSPITAL; HOSPITAL BED; HUMAN; ISRAEL; KLEBSIELLA; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HOSPITALS, GENERAL; HUMANS; ISRAEL; KLEBSIELLA; KLEBSIELLA INFECTIONS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE;

EID: 33846509415     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.07.011     Document Type: Article

References (14)

1. Bishara J., Livne G., Ashkenazi S., et al. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Isr. Med. Assoc. J. 7 (2005) 298-301
2. Bradford P.A. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14 (2001) 933-951
3. Colodner R., Raz R., Chazan B., and Sakran W. Susceptibility pattern of ESBL-producing bacteria isolated from inpatients to five antimicrobial drugs in a community hospital in northern Israel. Int. J. Antimicrob. Agents 24 (2004) 409-410
4. Friedland I.R., Isaacs R., Mixson L.A., Motyl M., and Woods G.L. Use of surrogate antimicrobial agents to predict susceptibility to ertapenem. Diagn. Microbiol. Infect. Dis. 43 (2002) 61-64
5. Jacoby G.A., Mills D.M., and Chow N. Role of β-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48 (2004) 3203-3206
6. Jacoby G.A., and Munoz-Price L.S. The new beta-lactamases. N. Engl. J. Med. 352 (2005) 380-391
7. Leblebicioglu H., Gunaydin M., and Esen S. Surveillance of antimicrobial resistance in gram-negative isolates from intensive care units in Turkey: analysis of data from the last 5 years. J. Chemother. 14 (2002) 140-146
8. Livermore D.M. Beta-lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8 (1995) 557-584
9. Paterson D.L., Ko W.C., Von Gottberg A., et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann. Intern. Med. 140 (2004) 26-32
10. Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. Clinical Laboratory Standards Institute document M100-S16 (2006) CLSI Press. Wayne, PA.
11. Perilli M., Dell'Amico E., and Segatore B. Molecular characterization of extended-spectrum beta-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey. J. Clin. Microbiol. 40 (2002) 611-614
12. Schwaber M.J., Navon-Venezia S., Schwartz D., and Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 49 (2005) 2137-2139
13. Valverde A., Coque T.M., Sánchez-Moreno M.P., Rollán A., Baquero F., and Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in pain. J. Clin. Microbiol. 42 (2004) 4769-4775
14. Winokur P.L., Canton R., Casellas J.M., and Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin. Infect. Dis. 32 (2001) S94-S103